You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Details for New Drug Application (NDA): 017601

✉ Email this page to a colleague

« Back to Dashboard

NDA 017601 describes OPTIMINE, which is a drug marketed by Schering and is included in one NDA. Additional details are available on the OPTIMINE profile page.

The generic ingredient in OPTIMINE is azatadine maleate. There are two drug master file entries for this compound. Additional details are available on the azatadine maleate profile page.

Summary for 017601

Tradename:	OPTIMINE
Applicant:	Schering
Ingredient:	azatadine maleate
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	1MG
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	No

Expired US Patents for NDA 017601

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	OPTIMINE	azatadine maleate	TABLET;ORAL	017601-001	Approved Prior to Jan 1, 1982	⤷ Try a Trial	⤷ Try a Trial
Schering	OPTIMINE	azatadine maleate	TABLET;ORAL	017601-001	Approved Prior to Jan 1, 1982	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.